Teva Pharmaceutical Industries (NYSE:TEVA) just secured U.S. FDA approval for at-home use of IGALMI sublingual film, the first treatment cleared for self-administered management of agitation in several serious mental health conditions.
Teva Pharmaceutical Industries has had a strong run over the past year, with a 1-year total shareholder return of 63.73% and a very large 3-year total shareholder return of about 4x. The 90-day share price return of 15.05% and year-to-date share price gain of 29.63% suggest momentum has been building, despite a 1-day pullback of 4.34% that leaves the stock at US$42.57.
Scan how other neuroscience and mental health players are priced by running through the hand picked 36 healthcare AI stocks that echo the kind of catalyst Teva Pharmaceutical Industries just reported.
The recent surge in Teva Pharmaceutical Industries now bumps up against a real question. Are you looking at a reset in how the business is priced, or a mood swing that ran ahead of fundamentals?
Teva Pharmaceutical Industries is trading at $42.57, while the analyst consensus Narrative on Simply Wall St points to a fair value of about $48.94 based on its long term earnings and cash flow forecasts. That gap reflects how much faith analysts put in Teva turning its current drug portfolio and pipeline into higher profits over time using an 8.64% discount rate.
The shift in Teva Pharmaceutical Industries toward higher value branded CNS drugs such as AUSTEDO, AJOVY and UZEDY is increasing the share of revenue tied to products that currently carry higher gross margins. Management links this shift to the goal of non GAAP operating margins of 30% and a higher EBITDA contribution over time.
See why 9 investors see Teva Pharmaceutical Industries as 13% undervalued.
Result: Fair Value of $48.94 (UNDERVALUED)
Still, the Teva Pharmaceutical Industries story only holds if key launches land on schedule and pipeline setbacks, such as the recent emrusolmin trial decision, remain isolated.
Find out about the key risks to this Teva Pharmaceutical Industries narrative.
If this Teva Pharmaceutical Industries story feels finely balanced between promise and risk, act while the facts are fresh and pressure test the thesis yourself with the 2 key rewards and 3 important warning signs.
Do not stop with one stock story when a wider set of ideas could sharpen your next move and keep your watchlist ahead of the crowd.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com